Search research articles
Contact Us
Filters
Showing results (421-430 of 580) with videos related to
Page
of 58
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Nature
|
July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2012
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment
Valentina Nardi, Peter M Sadow, Dejan Juric, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
A Argiris, J E Bauman, J Ohr, et al.
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Page
of 58
Search research articles
Search
Showing results (421-430 of 580) with videos related to
Sort By:
Page
of 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Nature
|
July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2012
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment
Valentina Nardi, Peter M Sadow, Dejan Juric, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
A Argiris, J E Bauman, J Ohr, et al.
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
The Lancet. Oncology
|
March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Page
of 58